Ignite Creation Date:
2024-05-06 @ 3:11 AM
Last Modification Date:
2024-10-26 @ 11:29 AM
Study NCT ID:
NCT02225002
Status:
COMPLETED
Last Update Posted:
2018-08-28
First Post:
2014-08-22
Brief Title:
Phase 1 Open-Label Dose-Escalation Study of CP-870893 in Patients With Solid Tumors
Sponsor:
Abramson Cancer Center at Penn Medicine
Organization:
Abramson Cancer Center at Penn Medicine
Study Overview
Official Title:
Phase 1 Open-Label Dose-Escalation Study of CP-870893 in Patients With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CD40 a member of the Tumor Necrosis Factor receptor superfamily is expressed on many tumor types including melanoma prostate colon breast renal pancreatic and nonsmall cell lung cancers In preclinical models activation of CD40 results in increased antigen presentation and induction of apoptosis CD40 is also expressed on antigen presenting cells APCs B cells dendritic cells monocytes and is a key regulator of both cellular and humoral immune responses Activation of CD40 by CP-870893 an agonistic anti-CD40 monoclonal antibody enhances host immune responses and abrogates the growth of tumors independently of the expression of CD40 on tumor cells Therefore it is hypothesized that therapeutic intervention with CP-870893 may be beneficial to a large number of cancer patients either through an immunomodulatory effect or through a direct effect on CD40-positive tumor cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None